Related Experiment Video
Updated: May 6, 2026
The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
Published on: February 28, 2012
Breaking boundaries: exploring recent advances in anticoagulation and thrombosis management: a comprehensive review
Zaheer Qureshi1, Faryal Altaf2, Abdur Jamil3
1The Frank H. Netter M.D. School of Medicine at Quinnipiac University, Bridgeport, Connecticut, USA.
Insights
New anticoagulants show promise in reducing bleeding and thromboembolic events. Ongoing research is vital for personalized anticoagulation therapy and improved patient outcomes in managing these disorders.
Area of Science:
- Cardiology
- Hematology
- Pharmacology
Background:
- Thromboembolic disorders are a major global cause of illness and death.
- Effective anticoagulation and thrombosis management are critical for preventing severe complications.
- Advancements in anticoagulant therapies are essential for improving patient outcomes.
Purpose of the Study:
- To review recent advancements in anticoagulation therapies and drug delivery systems.
- To assess the effectiveness and safety of novel anticoagulants.
- To identify current challenges and future directions in anticoagulation.
Main Methods:
- Systematic review of recent clinical trials, meta-analyses, and guideline publications.
- Analysis of key studies including PACIFIC-AF, RIVER, ENAVLE, ENVISAGE-TAVI AF, and ARCADIA.
- Evaluation of safety and efficacy data for new anticoagulant agents.
Main Results:
- Asundexian showed a 34% reduction in bleeding vs. Apixaban (PACIFIC-AF).
- Rivaroxaban reduced bleeding by 20% vs. warfarin (RIVER).
- Edoxaban decreased thromboembolic events by 3.7% vs. warfarin (ENAVLE) and was noninferior in preventing events but increased bleeding slightly (ENVISAGE-TAVI AF). Apixaban and aspirin showed similar stroke rates (ARCADIA).
Conclusions:
- Novel anticoagulants and drug delivery systems offer potential benefits for thromboembolic disorders.
- Patient-specific responses and monitoring remain areas for further investigation.
- Continuous innovation is needed to optimize anticoagulation practices and personalize treatments.
Background:
Thromboembolic disorders globally contribute to morbidity and mortality, emphasizing adequate anticoagulation and thrombosis management. Therapeutic advances are essential in preventing complications like pulmonary embolism, stroke, and myocardial infarction. This review summarizes recent anticoagulation advances, current challenges, future directions, and novel anticoagulants and drug delivery systems on clinical outcomes.
Methods:
This paper assesses the effectiveness and safety of new anticoagulants through a systematic review of recent clinical trials, meta-analyses, and guideline publications. Key studies, including PACIFIC-AF, RIVER, ENAVLE, ENVISAGE-TAVI AF, and ARCADIA, were analyzed to provide a perspective on therapeutic advancements.
Results:
The review highlights key findings from vital clinical trials. Asundexian, in the PACIFIC-AF trial, demonstrated a 34% reduction in bleeding events compared to Apixaban. In the RIVER trial, Rivaroxaban reduced significant bleeding events by 20% compared to warfarin in patients with bioprosthetic mitral valves. In the ENAVLE trial, Edoxaban achieved a 3.7% decrease in thromboembolic events compared to warfarin without increasing significant bleeding rates. In the ENVISAGE-TAVI AF trial, edoxaban was noninferior to VKAs in preventing thromboembolic events but showed a slight increase in major bleeding events by 1.5%. Lastly, the ARCADIA trial highlighted that apixaban did not significantly reduce recurrent stroke risk compared to aspirin, with both treatments having an annualized stroke rate of 4.4%.
Conclusion:
Advances in anticoagulant therapies and drug delivery systems aim to enhance patients' clinical outcomes for thromboembolic disorders. While recent trials show promising data, ongoing patient-specific responses and monitoring challenges require further research. Continuous innovation and investigation are essential to refine anticoagulation practices and tailor treatments.
Related Concept Videos
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:24Disorders of Hemostasis
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
01:29Venous Thrombosis III: Interprofessional Care
01:30Venous Thrombosis IV: Nursing Management